Skip to Content

Tilray Brands Inc TLRY

Morningstar Rating
CAD 2.34 −0.06 (2.50%)
View Full Chart
Unlock our analysis with Morningstar Investor

Company Report

Price vs Fair Value

TLRY is trading at a 553% premium.
Price
CAD 2.34
Fair Value
CAD 3.10
Uncertainty
Very High
1-Star Price
CAD 4.11
5-Star Price
CAD 1.27
Economic Moat
Rsf
Capital Allocation
Xgwkmxq

Bulls Say, Bears Say

Bulls

Tilray's better financial health and profitability lead compared with Canadian peers positions it to lead its home market.

Bears

The existence of the illicit market limits the potential price increases Tilray can push through to consumers.

Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if TLRY is a good fit for your portfolio.

News

Trading Information

Previous Close Price
CAD 2.40
Day Range
CAD 2.322.37
52-Week Range
CAD 2.044.64
Bid/Ask
CAD 2.33 / CAD 2.36
Market Cap
CAD 1.93 Bil
Volume/Avg
559,966 / 1.7 Mil

Key Statistics

Price/Earnings (Normalized)
Price/Sales
1.66
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield
0.08%

Company Profile

Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. US exposure consists of CBD products and alcohol.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Stock Style Box
Small Value
Total Number of Employees
1,600

Competitors

Valuation

Metric
TLRY
CRON
CGC
Price/Earnings (Normalized)
1,371.46
Price/Book Value
0.400.791.56
Price/Sales
1.669.142.15
Price/Cash Flow
Price/Earnings
TLRY
CRON
CGC

Financial Strength

Metric
TLRY
CRON
CGC
Quick Ratio
0.9626.511.09
Current Ratio
1.9228.191.58
Interest Coverage
−4.39−3.63
Quick Ratio
TLRY
CRON
CGC

Profitability

Metric
TLRY
CRON
CGC
Return on Assets (Normalized)
−1.42%−0.28%−17.78%
Return on Equity (Normalized)
−1.82%−0.29%−46.87%
Return on Invested Capital (Normalized)
−0.92%−4.97%−16.41%
Return on Assets
TLRY
CRON
CGC
See how this stock stacks up to its competitors with Morningstar Investor

Drug Manufacturers - Specialty & Generic Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Zoetis Inc Class A
ZTS
YlmkbvkdkrJldcj$79.8 Bil
Merck KGaA ADR
MKKGY
BwmxdyxbRcrksk$71.7 Bil
Haleon PLC ADR
HLN
NhpgfgtrnCnbg$37.9 Bil
Dr Reddy's Laboratories Ltd ADR
RDY
WbmdtbmwVxp$13.0 Bil
Viatris Inc
VTRS
GfjcztrQxvjd$12.3 Bil
Catalent Inc
CTLT
NjrkrmhmfLtxkxw$10.3 Bil
Perrigo Co PLC
PRGO
LxywtnqyYpkm$3.5 Bil
Prestige Consumer Healthcare Inc
PBH
JqtskjxfvTcsrgsj$3.4 Bil
Curaleaf Holdings Inc
CURLF
TqkljhmtMft$2.8 Bil
Green Thumb Industries Inc
GTBIF
LjnnffqzYpnrh$2.7 Bil

Sponsor Center